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History of MS
■

Thought to be immune mediated
– Virally triggered in genetically susceptible host

■

Treatments
– Acute attacks: ACTH in 1970s–1980s
– Disease modification in 1990s
– Symptomatic management

■

Diagnostic tests
– MRI in 1980s
– New MRI techniques

What We Know Now…
■

Most common neurological disease of young adults

■

Chronic disease of the CNS
– Inflammation, demyelination, axonal degeneration

■

Approximately 350,000 cases in US

■

2/3 of MS patients are women

■

Associated with Northern European ancestry

■

Age of onset: 15–55
– Usually diagnosed in 20s–30s

Statistics
■

Worldwide distribution
– High prevalence 30+/100,000
• Northern US and Canada
• Most of Europe
• Southern Australia
• New Zealand
• Northeast Russia

Pathology
■

White matter lesions in CNS
– Surrounded by plasma cells,
immunoglobulins, macrophages, and
lymphocytes

■

Grey Matter
– Cortex, Basal Ganglia

■

Inflammation
– Myelin injury and destruction
– Axonal injury and destruction

Demyelination and Axonal
Transection
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Reprinted with permission from Trapp BD et al. N Engl J Med. 1998;338:278-285. Copyright  1998 Massachusetts Medical Society. All rights reserved.

Disease Course
■

85%–90% of patients present with a RR pattern of
neurological symptoms

■

10%–15% never have relapses (PP)

■

Historically - After approximately 10 years, nearly 50%
of RR patients will show a progressive pattern to their
disease
– This percentage grows with time
– Now believed longer than 10 years due to earlier
treatment
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Natural History Over Time
RRMS
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Disease Type at Diagnosis

Weinshenker BG et al. Brain. 1989;112:133-146.

58%

Disease Type at 11–15 Years
After Diagnosis (Among Those
With RRMS at Diagnosis)

Symptoms
■
■
■
■
■

Fatigue
Sensory disturbances
Visual disturbances
Elimination dysfunction
Gait Disturbances

■

Spasticity
■ Pain
■ Tremor
■ Cognitive

Symptoms vary widely in incidence and severity.

Diagnosis of MS
■

Basic principles
– Demographic profile
• Female, Caucasian, young adult
– Clinical presentation
• Symptomatic disease, Abnormal exam
• Flare or attack = 24 hours – up to 3 or more weeks
– Laboratory profile
• MRI
• CSF
• Evoked potentials
• Exclusion of other diagnoses

MS - Clinical Presentation
■

Sensory tracts
– 21%–55% of patients
– Most common presenting symptom
•
•
•
•
•
•

Tingling, burning, “Novocaine-like,” band-like, squeezing
Lhermitte’s
Neuritic pain
Exam - Diminished vibratory sensation
Exam - Impaired position sense
“Useless hand” syndrome
– Sensory loss, loss of position sense
– Mobility preserved

MS - Clinical Presentation
■

Corticospinal tracts
– 32%–41% of patients
•
•
•
•

Heaviness, weakness
Abnormal DTRs
Positive Babinski response
Spastic limb weakness

MS - Clinical Presentation
■

Brainstem
– Eye movement abnormalities
• Diplopia at onset in about 7% of patients
• Nystagmus, INO
• Bilateral INO is almost pathognomonic for MS
– Vertigo

– Infrequently
• Dysarthria
• Peripheral 7th
• Hearing loss and tinnitus

MS - Clinical Presentation
■

Visual pathway
– Optic neuritis
• Presenting symptom in up to 25%
of patients
– Dimming or visual loss
– Loss of color vision
– Visual field defect

■

Cerebellar
– Gait ataxia, limb ataxia, tremor

MS - Clinical Presentation
■

Fatigue
– Present in up to 90% of patients with long-term MS
– Can be seen with any Flare/Attack

■

“Elimination” brainstem/spinal cord
– Occasionally present at onset of disease
– Bladder urgency, frequency, hesitation, nocturia
– Bowel constipation, infrequently involuntary bowel
movements

MS Diagnosis
■

Posner Criteria (1983)
– Two clinical attacks in Space and Time
– No other explanation
– Paraclinical Evidence (VEP and CSF)
• MRI not available

■

McDonald Criteria 2001
McDonald Criteria revised in 2005
McDonald Criteria revised in 2010

■
■

McDonald Diagnostic Criteria
■

Preserve traditional diagnostic criteria of
2 attacks of disease separated in space
and time
– Must be no better explanation
– Add specific MRI criteria, CSF findings, and analysis of evoked
potentials as means of identifying the second “attack”

■

Conclude that the outcome of the diagnostic workup should yield 1 of
3 outcomes:
– MS
– Possible MS
– Not MS

McDonald WI et al. Ann Neurol. 2001;50:121-127.

McDonald MRI Criteria - 2005
■

Abnormal MRI consistent with MS defined
as:
– Must have at least 3 of the following:
• 1 gadolinium-enhancing lesion or
9 hyperintense lesions if no
gadolinium-enhancing lesion
• 1 or more infratentorial lesions
• 1 or more juxtacortical lesions
• 3 or more periventricular lesions
– 1 cord lesion = 1 brain lesion

McDonald MRI Criteria
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2010 Revised McDonald MRI Criteria
■

Abnormal MRI consistent with MS defined as:
– Dissemination in Space
• >= 1 lesion at least 2 of the 4 characteristic areas:
Periventricular, juxtacortical, infratentorial, spinal cord
– Dissemination in Time
• Enhancing and Non-Enhancing lesions
• New Lesion
• New Clinical Attack
** LP and other Ancillary tests not required if no other
explanation and above clearly seen
** Can make diagnosis with single attack/first MRI

McDonald MRI Criteria
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Other Paraclinical Evidence
■

Abnormal CSF
– Oligoclonal IgG bands in CSF and not in
serum
– Or elevated IgG index

■

Abnormal evoked potentials (VER,
SSEP)
– Delayed but well-preserved waveform

Differential Diagnosis
■

Infection

■

– Lyme, syphilis, PML,
HIV, HTLV-1
■

Inflammatory
– SLE
– Sjögren’s, vasculitis,
sarcoidosis, Behçet’s
disease

Metabolic
– B12 deficiency, rare
familial diseases

■

CNS lymphoma
■ Degenerative spinal
disease
■ Motor neuron disease

Serum Testing
■
■
■
■
■
■

B12, folate
■
RPR, FTA
■
HIV
■
HTLV-1
■
ANA, SS-A, SS-B
Antiphospholipid antibodies

ESR, C-reactive protein
Thyroid function
Angiotension-converting
enzyme
Anti-acetylcholine receptor
antibodies
■ Long-chain fatty acids

MRI in MS
■

MRI Brain
– Classic Lesions = 90%–95%
sensitivity/specificity
– Newer data on Grey Matter Lesions
– Brain Atrophy

■

MRI Spinal Cord
– Lesions seen in 50%–75% of cases
• <= 1-2 vertebral levels
• >= 3 continuous lesions – think NeuroMyelitis
Optica

T1-Weighted Images

T1 Hypointensities
■

“Black holes”
– Thought to be areas of axonal loss
– Can be “black holes” that are temporary with a new lesion

■

Black holes not associated with a new lesion are thought
to be areas of permanent damage

T1 Black Holes

T2-Weighted Images

Conventional T2

FLAIR

FLAIR Image

FLAIR Image and T1 Black
Holes

Spinal MRI in MS
■
■
■
■
■

■

Spinal cord lesions in 75% of MS patients
Predominantly in C-spine
Usually dorsolateral or central and 0.5 cm
by 1–2 cm, and 1–2 vertebral segments
Less likely to enhance or cause cord swelling
More likely to cause progressive disease
T2 less predictive of disability than atrophy

Cord Lesion

Examples of BPF in MS

31-year-old male
Healthy control

36-year-old woman
RRMS (2 years)

43-year-old woman
SPMS (19 years)

BPF 0.87
z score = 0

BPF 0.85
z score = –2.6

BPF 0.71
z score = –20.8

Reprinted with permission from Rudick RA et al. Neurology. 1999;53:1698-1704.

MS Diagnosis
■

Two “other” Categories
– Clinically Isolated Syndrome
• First Clinical Attack
• MRI with 1 or 2 lesions
– Radiological Isolated Syndrome
• MRI with “Classic” MS lesions
• No clinical history
** VEP, Cervical Spine, +/- LP

Radiological Evidence
■

Natural history studies demonstrate that up to 88% of patients with
1 attack and MRI lesions go on to convert to CDMS.1,2

Development of CDMS, stratified for baseline MRI findings.
Modified from Miller et al.
Study

Normal MRI

Abnormal MRI

Brex et al.

19%

88%

Optic Neuritis Study Group
(final follow-up–15 y)3

25%

72%

Minneboo et al.

24%

72%

Tintore et al.

8%

63%

CDMS = clinically definite multiple sclerosis.
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Relationship Between No. of T2 Lesions at Baseline
and Clinical Outcome by 20 Years in CIS Patients
20-Year Follow-Up of Prospectively Recruited CIS Cohort

Baseline Lesions
0
(n = 34)

1-3
(n = 22)

4-9
(n = 20)

10+
(n = 31)

CDMS at 20 yrs

7 (21%)

18 (82%)

17 (85%)

25 (81%)

EDSS >3 at 20 yrs

9 (26%)

8 (36%)

10 (50%)

20 (65%)

EDSS ≥6 at 20 yrs

2 (6%)

4 (18%)

7 (35%)

14 (45%)

Fisniku LK, et al. Brain. 2008;131:808-817.

39

Proposed Algorithm for Evaluating Treatment Response
in RRMS

40
Rio J, et al. Nat Rev Neurol. 2009;5:553-560.

MS Treatment - Injectables
■

Interferons
–
–

BetaSeron (QOD,SQ)
Avonex (Weekly, IM)

–

Side Affects

Rebif (TIW, SQ)
Extavia (QOD,SQ)

• Flu like symptoms, Fatigue, Headache, Injection Problems

■

Treatment tricks
–
–
–

■

Pre-medicate with Tylenol or Advil
Take medication before bed. Can disrupt sleep, so may need morning dosing
Determine hours until “worse” flu like symptoms and adjust shot to have them
occur when sleeping

Labs
–

LFTs Q6 months; TSH - yearly

MS Treatment - Injectable
■

Copaxone (CoPolymer)
– Believed to be equal to Interferons when used early (CIS)
– Presently given daily - SQ
– Probable change to every other day (double dose
amount) in 2013

– Side Affects
• Injection site reaction of itching at site
• Chest Pain (rare)

MS Treatment - Infusion
■

Tysabri
– Used for failing 1st line
– Aggressive 1st line
– Progression while on 1st line
– Connected to PML
• 24 months use
• Prior Chemotherapy
• JC virus +

– Can have steroids 2 weeks before infusions for flares
– Continued reports of improving fatigue, cognitive and strength with
starting

MS Treatment - Infusion
■

Tysabri
– Labs/Imaging
• Check monthly labs, urine at time of infusion
• Check JC Virus before starting and every 3 months after
– Available through Quest Labs

• Check MRI every 6 months JC(+) or yearly JC(-)

Requirements for PML Development:
JCV Mutation
Evidence from multiple patient populations supports the theory that
specific JCV mutations contribute to the development of PML

■

Wild-type / benign JCV
– Transmittable form
– Commonly found
in the kidney of
healthy patients
– May replicate
periodically

■

Viral
mutations

Pathogenic JCV
– Active variant found
in brains of PML
patients
– Contains mutations
believed to increase
viral replication and
pathogenicity
– Causes destruction
of myelin-producing
cells of the brain

Evaluation of JCV DNA Testing
Quantitative PCR testing for JCV DNA
■

1,400 MS patients checked (13,000 samples)
– Blood Tests
• <1% and not associated with the development of PML

– Urine samples
• 25% Positive (Prior studies = 55% )

1 / 3 patients who developed PML were urinary JCV DNA negative
at all time points tested
**Results suggested JCV DNA detection in blood or urine is not
reliable for assessment of PML risk

Indirect Testing
■

Check Anti-JCV Antibodies (serum)
– Initial exposure to the virus results in formation
of anti-JCV antibodies

■

Once seropositive, antibodies generally
persist even during viral latency

■

Currently the test is available through Quest
Labs

Anti-JCV Antibody vs. JCV DNA
Testing
STRATIFY JCV Test

JCV DNA Test

Uses

• Detects past JCV exposure
(does not diagnose PML)
• Can be used for assessment of PML risk

• Diagnostic (CSF) for PML
• Denotes JCV actively replicating in the
brain

Test type

• ELISA

• PCR

Sample

• Blood

• Blood, urine, CSF

Detects

• Antibodies to JCV

• Presence of viral components (DNA)

Results
indicate:

• Any past exposure to JCV

• JCV exposure, but only when JCV is
actively replicating and shedding into
test sample

Ongoing Research Evaluation
■

Among >800 MS patients tested:
– 46% were anti-JCV antibody negative

– 54% were anti-JCV antibody positive

■

A prospective clinical trial of >30,000 MS patients is ongoing to
evaluate STRATIFY JCV to:
– Assess the prevalence of JCV in MS patients
– Determine changes in JCV antibody status over time
– Identify the correlation between JCV positivity and PML development

MS Oral Treatments
■

Gilenya – Fingolimod

■
■

Initially investigated to prevent renal allograft rejection
Chemically modified derivative of a fungal metabolite

■

Studied against current Interferon (injectable) with:
–

45 % reduction in relapse rate compared to Interferon.

MS Oral Treatments
■

Gilenya - Fingolimod
– Mechanism of Action
• Agonist to S1P receptors
– When Phosphorylated

• Gilenya acts to sequester circulating lymphocytes into secondary
lymphoid organs
• No effect on lymphocyte induction, proliferation, or memory function

• Lymphocyte counts decreased by 72-77%
• Peripheral reduction of
– CD3+, CD4+, CD8+,
– CD45RA+ (naive T cells),

- CD45RO+ (memory T cells),
- CD19+ cells

Gilenya - Cardiac
IFN β-1a 30µg IM
Once Weekly

Oral Fingolimod
0.5mg

Oral Fingolimod
1.25mg

Bradycardia

0

2 (0.5%)

10 (2.4%)

Second Degree AV Block

0

1 (0.2%)

3 (0.7%)

Firist Degree AV Block

0

1 (0.2%)

2 (0.5%)

Appendicitis

2 (0.5%)

0

2 (0.5%)

Herpes viral infections

1 (0.2%)

1 (0.2%)

3 (0.7%)

0

0

2 (0.5%)

Number (%) of
Participants
Cardiac Disorder

Infections

Dyspnea

* Cardiac Complications with First dose believed due to internalization of SP receptors

MS Oral Therapies
Gilenya (Fingolimod)
■

FDA Requirements

■

A. 6 hour Observation with EKG
with first dose and prior to
leaving
– Blood pressure every
hour
B. OCT exam before and at 3-4
months
C. Varicella Titer

■
■

■

MS Center of Lehigh Valley
Gilenya Protocol
– A. 6 hour Telemetry
Monitoring
*Dr. Spikol
– B. OCT exam before and
at 3-4 months
– C. Varicella Titer
– D. Cancer Screening
• Dermatology
• Male/Female
Standard Guidelines
– Breast, Pelvic,
Testicular, Colon

MS Oral Therapies – Aubagio
(Teriflunomide)
■

Aubagio
– FDA approved October 2012
– Active component of Leflunomide

■

Major Side Effects
– Liver Affect
– Alopecia
– Birth Defects

MS Oral Therapies - Teriflunomide

Leflunomide

Teriflunomide
(A77 1726, HMR1726)

■

Teriflunomide is the active metabolite of leflunomide
–

■

Leflunomide is FDA-approved in adults for the treatment of active rheumatoid arthritis

Teriflunomide is being developed for the treatment of multiple sclerosis:
–

Eliminates other metabolites of leflunomide
• Although it is a minor pathway, these metabolites may themselves have adverse effects

–
–

Avoids the hepatic metabolism of leflunomide to teriflunomide
Reduces CYP450 involvement compared with leflunomide, which may decrease
potentially clinically significant drug–drug interactions

Teriflunomide: Proposed MOA in MS
Dihydroorotate Dehydrogenase (DHODH)

A77 1726

TERIFLUNOMIDE

Teriflunomide selectively and reversibly inhibits DHODH
–

a key mitochondrial enzyme in de novo pyrimidine synthesis required by
rapidly dividing lymphocytes
– Cystostatic
– Limit over-activation of the activated and autoimmune Lymphocytes
– Protective immunity is not significantly affected by Teriflunomide

MS Oral Therapies Teriflunomide
■

Leflunomide Experience
– Cases of Lymphoma have been seen
• However increase in case with all RA treatments
(MethoTrexate, Cyclosporin)

– Severe Liver Necrosis with fatalities have
occurred
• Seen within first 6 months of therapy

– Severe Infections have been seen
• TB, Pneumonia, PCP, Mycotic

Teriflunomide
■

TEMSO (Teriflunomide Multiple Sclerosis
Oral trial)
– Decrease in Annual Relapse Rate (vs Placebo)
• 7 mg dose – 31.2 %
• 14 mg dose – 31.5 %

■

TOWER
– Decrease in Annual Relapse Rate (vs Placebo)
• 7 mg – 22.3 %
• 14 mg – 36.3 %

MS Oral Therapies - DMF
■

DMF (dimethyl fumarate)
– Derived from Fumaderm, an oral therapy of fumaric acid
esters
– Approved to treat psoriasis in Germany

■

Initial Proposed FDA approval – December 2013

■

Proposed for Mid 2013
– FDA needed extended time to review Data.
– Did not require more / additional data

MS Oral Therapies - DMF
■

DMF (DiMethyl Fumarate)
– Therapeutic mechanism in MS is speculative
• Psoriasis Data – Beneficial effect coincides with Lymphocytopenia
» Decreased by 40%-60%

–
–
–
–

Down-regulation of proinflammatory cytokines
Increase in Antiinflammatory cytokine IL-10
Upregulation of Nuclear Factor 2
Induces Anti-Inflammatory Stress Protein HO-1

• Protective antioxidant pathway in CNS
– Unpublished data in the EAE model

MS Oral Therapies - DMF
■

DEFINE:
– Placebo-controlled, 1011 patients
• Low-dose : 240 mg BID
• High-dose : 240 mg TID
• Annualized relapse rate

– Results
• Two year ARR –
– Placebo = 36%, BID = 17%, TID = 19%

■

CONFIRM:
–
–
–
–

High- and low-dose vs Copaxone®
Subjects (N~1232): RRMS by MacDonald, EDSS <5
Primary outcome: Annualized relapse rate
Results
• Two year ARR –
– Copaxone = 29%, BID = 22%, TID = 20%

Conclusion
■

MRI is now major diagnostic tool
– Can diagnose with first attack / MRI
– Clinically Isolated Syndrome and
Radiological Isolated Syndrome
categories

■

New Oral Therapies

